Conditions: Breast Neoplasms Breast Cancer Cancer of the Breast
Keywords: Metastatic breast cancer Triple negative breast cancer Estrogen receptor (ER)/progesterone receptor (PR)/human epidermal growth factor receptor 2 (HER2)-negative breast cancer
Allocation: NA | Intervention model: SINGLE_GROUP
Enrollment: 5
Healthy volunteers: no

Brief summary:
The patient is being asked to join this clinical research study to find out if lapatinib, an agent that targets a protein, called epidermal growth factor receptor (EGFR) on the surface of cancer cells in combination with everolimus, an agent that targets a protein in the cancer cell, called mammalian target of rapamycin (mTOR) is effective in metastatic triple negative breast cancers that are no longer controlled by standard chemotherapy.

Detailed description:

Arms:
arm 1: None

Interventions: intervention 1: Lapatinib and Everolimus
Intervention descriptions: intervention 1: Lapatinib: 1250 mg by mouth daily

Everolimus: 5mg by mouth daily

Protocol document: